Loading...
Loading...
Browse all stories on DeepNewz
VisitResearchers Develop AI-Based Immunotherapy for Glioblastoma Using ROBO1 CAR T Cells
Aug 2, 2024, 09:09 AM
Researchers are pioneering a new immunotherapy approach using artificial intelligence (AI) to treat glioblastoma, a highly aggressive form of brain cancer. This innovative method, developed by scientists at institutions including Keck School of Medicine at USC and Cambridge University, aims to transform cancer treatment. The approach involves developing AI models to create new tools for combating cancer. A promising therapy treatment has been discovered that can kill glioblastoma cells by targeting a newly-discovered brain pathway, as reported in Nature Medicine. Additionally, the use of ROBO1 CAR T cells has shown potential as a potent immunotherapy for glioblastoma and other invasive brain cancers. This Canadian-developed treatment could significantly impact the fight against the most aggressive brain cancers.
View original story
Markets
No • 50%
Yes • 50%
Publication in a reputable peer-reviewed medical journal
No • 50%
Yes • 50%
Clinical trial results published in a reputable medical journal or official announcement from the research institutions
Yes • 50%
No • 50%
Official FDA approval announcement
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Official announcements from research institutions or publications in reputable medical journals
Keck School of Medicine at USC • 25%
Other • 25%
A Canadian Institution • 25%
Cambridge University • 25%
Official announcements from research institutions or clinical trial registries
Other • 25%
Glioblastoma • 25%
Medulloblastoma • 25%
Astrocytoma • 25%
Results published in reputable medical journals or official announcements from research institutions